SCHEMBL14967435

SCHEMBL14967435

Cc1nc(C)c(CNC(=O)c2ccc(Oc3ccccc3)cc2)c(O)n1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 9/20 0.57
HPGD P15428 2/20 0.54
MMP13 P45452 4/20 0.54
LMNA P02545 3/20 0.54
CYP3A4 P08684 2/20 0.54
HTT P42858 2/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
ALDH1A1 P00352 1/20 0.50
MMP1 P03956 1/20 0.48
PPARG P37231 2/20 0.47
PPARA Q07869 2/20 0.47
EPHX2 P34913 1/20 0.47
MMP2 P08253 2/20 0.47
STAT3 P40763 1/20 0.47
GRM5 P41594 1/20 0.47
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA9 Q16790 1/20 0.46
MEN1 O00255 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14967422 0.82 MAPK14 (0.56) MAPK14HPGDMMP13LMNACYP3A4
SCHEMBL14966690 0.81 MAPK14 (0.54) MAPK14HPGDMMP13LMNACYP3A4
SCHEMBL14966950 0.80 MAPK14 (0.55) MAPK14HPGDMMP13LMNACYP3A4
SCHEMBL14966964 0.80 MAPK14 (0.53) MAPK14HPGDMMP13LMNACYP3A4
SCHEMBL14966960 0.80 SMN1; SMN2 (0.54) MAPK14HPGDMMP13LMNACYP3A4
SCHEMBL14972028 0.79 MAPK14 (0.55) MAPK14HPGDMMP13LMNACYP3A4
SCHEMBL14967014 0.78 MAPK14 (0.55) MAPK14HPGDMMP13LMNACYP3A4
SCHEMBL8738317 0.73 HPGD (0.97) MAPK14HPGDMMP13LMNACYP3A4
SCHEMBL31061058 0.73 MAPK14 (1.00) MAPK14HPGDMMP13LMNACYP3A4
SCHEMBL14966646 0.73 KLKB1 (0.46) MAPK14HPGDMMP13LMNACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9206128-B2 Modulators of methyl modifying enzymes, compositions and uses thereof CONSTELLATION PHARMACEUTICALS, INC. (US) 2015-12-08 US disclosed
US-9206128-B2 Modulators of methyl modifying enzymes, compositions and uses thereof CONSTELLATION PHARMACEUTICALS, INC. (US) 2015-12-08 US disclosed
US-20140288123-A1 MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF CONSTELLATION PHARMACEUTICALS, INC. 2014-09-25 US disclosed
EP-2780014-A1 MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF Constellation Pharmaceuticals, Inc. (US) 2014-09-24 EP disclosed
WO-2013075083-A1 MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF CONSTELLATION PHARMACEUTICALS (US) 2013-05-23 WO disclosed
WO-2013075083-A1 MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF CONSTELLATION PHARMACEUTICALS (US) 2013-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140288123-A1 MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF TET1, TET3, EHMT2 MAPK14 4092/4885HPGD 1295/4885MMP13 2054/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.